Login to Your Account

BioMarin Reducing Orapred Sales Force, Blames Generics

By Randall Osborne

Thursday, July 7, 2005
Just more than a year after disclosing its plan to buy out Ascent Pediatrics Inc., thereby gaining the pediatric asthma drug Orapred and a 66-person sales force, BioMarin Pharmaceutical Inc. is laying off 58 people - mostly from that team - in response to the launch of two new generic forms of the corticosteroid. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription